<i id='3F3CDB9B3D'><strike id='3F3CDB9B3D'><tt id='3F3CDB9B3D'><pre id='3F3CDB9B3D'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
The high cost of giving birth even with insurance 
EU moves toward latest gene techniques in food production to counter climate change, shortages 
Psychedelics group wrestles with new pharma identity 
Delta passengers in Vegas fall sick while waiting on flight in triple 
Continuity nursing helped my family in our darkest PICU moments 
A new ‘biological computer' targets cancer while sparing healthy cells
The high cost of giving birth even with insurance 
The leaders of Italy and Poland say European Union should focus on stopping migration 
Supreme Court strikes down use of affirmative action 
Former New York Mayor de Blasio and wife announce separation, but not divorce 
Hollywood unions extend contract negotiations for actors 
The stock market has soared this year, but will it last? Experts weigh in 
How one medical school became remarkably diverse 
Pope Francis asks Church to identify 21st 
Peter Hotez and the public health issue of online harassment 
